Welcome to Global BD&L and M&A at Novartis
Within BD&L our mission is:
To create long term collaborations
to access therapeutic products, technology platforms and break through innovations with the potential to reimagine medicine, to ease suffering and to enhance the quality of life.
To create long term shareholder value
by refocusing our pipeline to the strategic priorities through divestments of assets.
To build a wide network within the life science community
to have access to new innovation and to explore opportunities in our core strategic areas as well as outside which have the potential to set our future direction.
Novartis to acquire Endocyte
Expanding expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms
NVS @ JP Morgan Conference 2019
San Francisco January 7-10, 2019